Table 1.
Baseline characteristics of the included studies.
| ELIXA(2015) | LEADER(2016) | SUSTAIN-6(2016) | EXSCEL(2017) | Harmony Outcomes (2018) | REWIND(2019) | PIONEER 6(2019) | AMPLITUDE-O(2020) | |
|---|---|---|---|---|---|---|---|---|
| Drug | Lixisenatide | Liraglutide | Semaglutide | Exenatide | Albiglutide | Dulaglutide | Semaglutide | Efpeglenatide |
| paticipants | 6068 | 9341 | 3297 | 14752 | 9463 | 9901 | 3183 | 4076 |
| Usage | 20μg sc qd | 1.8mg sc qd | 0.5 or 1mg sc qw | 2mg sc qw | 30 or 50mg qw | 1.5mg sc qw | 14mg po qd | 4 or 6mg sc qw |
| mean follow up (years) | 2.1 | 3.8 | 3.1 | 3.2 | 1.6 | 5.4 | 1.3 | 1.8 |
| Mean age(years) | 60.3 ± 7 | 64.3 ± 7 | 64.6 ± 7 | 61.9 ± 9 | 64.1 ± 7 | 66.2 ± 7 | 66.0 ± 7 | 64.5 ± 7 |
| Male n (%) | 4207(69.3%) | 6003(64.3) | 2002(60.1%) | 9149(62%) | 6569(69.4%) | 5312(53.7%) | 2176(68.4%) | 2732(67%) |
| BMI(kg/m2) | 30.2 ± 6.2 | 32.5 ± 6.3 | 32.8 ± 6.2 | 31.8 ± 6.4 | 32.3 ± 5.9 | 32.3 ± 5.7 | 32.3 ± 6.5 | 32.7 ± 6.3 |
| Established CVD n(%) | 6068(100%) | 7598(81%) | 2735(83%) | 10782(73%) | 9463(100%) | 3109(31.4%) | 2695(84.7%) | 3650(89.6%) |
| Duration of diabetes(years) | 9.2 ± 8.1 | 12.8 ± 8.0 | 13.9 ± 8.1 | 13.1 ± 8.3 | 14.2 ± 8.6 | 10.5 ± 7.2 | 14.9 ± 8.5 | 15.4 ± 8.2 |
| Mean HbA1c (%) | 7.7 ± 1.5 | 8.7 ± 1.6 | 8.7 ± 1.5 | 8.1 ± 1.0 | 8.7 ± 1.5 | 7.3 ± 1.1 | 8.2 ± 1.6 | 8.9 ± 1.5 |
Data are mean ± SD, unless otherwise noted.